Table II.
Prognostic factors of OS in 399 patients with HCC.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age, years | ||||||
| >48 vs. ≤48 | 0.932 | 0.750–1.758 | 0.525 | |||
| Gender | ||||||
| Male vs. female | 1.273 | 0.874–1.853 | 0.208 | |||
| HBsAg | ||||||
| Positive vs. negative | 1.382 | 1.043–1.830 | 0.024 | 1.369 | 1.023–1.832 | 0.035 |
| Cirrhosis | ||||||
| Yes vs. no | 1.100 | 0.843–1.435 | 0.484 | |||
| Tumor size, cm | ||||||
| ≥10 vs. <10 | 1.699 | 1.347–2.143 | <0.001 | 1.679 | 1.310–2.152 | <0.001 |
| Tumor encapsulation | ||||||
| None vs. complete | 1.412 | 1.136–1.756 | 0.002 | 1.138 | 0.899–1.441 | 0.283 |
| Tumor no. | ||||||
| Multiple vs. solitary | 1.599 | 1.275–2.006 | <0.001 | 1.123 | 0.872–1.448 | 0.369 |
| Vascular invasion | ||||||
| Present vs. absent | 2.051 | 1.548–2.718 | <0.001 | 1.758 | 1.305–2.367 | <0.001 |
| Differentiation | ||||||
| III–IV vs. I–II | 1.298 | 1.024–1.645 | 0.031 | 1.245 | 0.973–1.594 | 0.082 |
| TNM stage | ||||||
| II–III vs. I | 1.678 | 1.346–2.091 | <0.001 | |||
| AFP, µg/l | ||||||
| >25 vs. ≤25 | 1.284 | 1.107–1.622 | 0.036 | 1.191 | 0.935–1.516 | 0.157 |
| GGT, U/l | ||||||
| >50 vs. ≤50 | 1.631 | 1.312–2.028 | <0.001 | 1.486 | 1.184–1.866 | 0.001 |
| HGB, g/l | ||||||
| ≤110 vs. >110 | 1.183 | 0.905–1.546 | 0.007 | 1.205 | 0.861–1.686 | 0.278 |
| MCH, pg | ||||||
| ≤27 vs. >27 | 1.737 | 1.346–2.242 | <0.001 | 1.845 | 1.393–2.445 | <0.001 |
OS, overall survival; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen; TNM, tumor-node-metastasis; AFP, α-fetoprotein; GGT, γ-glutamyl transpeptidase; HGB, hemoglobin; MCH, mean corpuscular hemoglobin.